Delivery Order SPE2DB20D9127-SPE2DB25FPRR1
- Not listed
- The Defense Logistics Agency has awarded a delivery order valued at $3,868.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the provision of Xolair 150 mg/ml syringes. The contract is firm fixed-price with an ultimate completion date of September 17, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the...
- The Defense Logistics Agency awarded a $1,547.40 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. The contract is firm fixed-price with an ultimate completion date of September 18, 2025, and carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at approximately $500 million...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $7,737 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of Xolair 75 mg/0.5 ml syringe 0.5 ml, with an ultimate completion date of October 30, 2024. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) awarded to DMS Pharmaceutical Group Inc. under the DLA's...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $4,642.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 75 mg/0.5 ml syringes. The delivery order, issued on September 18, 2025, with an ultimate completion date of October 9, 2025, carries no set-aside designation. DMS Pharmaceutical Group is executing this order under its larger Indefinite Delivery Contract with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $44,651.52 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. This firm fixed-price delivery order, issued on September 18, 2025, with an ultimate completion date of October 9, 2025, represents a standard procurement action with no set-aside designation. The award falls under DMS Pharmaceutical Group's larger...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. The contract, awarded on September 25, 2025, carries a ceiling value of $1,860.48 with an ultimate completion date of October 17, 2025. This delivery order utilizes a firm fixed-price structure and was issued without a set-aside designation. The award represents a discrete...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. The contract, valued at $27,907.20 with a firm fixed-price structure, is scheduled for completion by September 5, 2025, and was awarded on August 14, 2025. This delivery order carries no set-aside designation and leverages DMS Pharmaceutical Group's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, valued at $1,547.40 with an ultimate completion date of September 10, 2025, was issued without set-aside designation. DMS Pharmaceutical Group competes effectively in federal procurement leveraging its small business status and established...
- The Defense Logistics Agency awarded a delivery order valued at $7,737.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. This firm fixed-price delivery order, issued on September 10, 2025, is scheduled for ultimate completion by October 1, 2025, with performance taking place at the awardee's Park Ridge facility. The contract was awarded without a set-aside designation,...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $7,737.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the supply of Xolair 150 mg/ml syringes and is part of a larger Indefinite Delivery Contract (IDC) worth up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. This IDC enables the DLA to issue delivery orders for a...
- SPE2DB20D9127Indefinite Delivery Contract
- SPE2DB20D9127-SPE2DB25FPRR1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,737.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The contract employs firm fixed-price pricing with an ultimate completion date of October 20, 2025, and carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA's SPE2DB program, a $499.999 billion contract vehicle valid through November 2026 that enables the agency to issue orders for a comprehensive range of pharmaceutical products supporting military healthcare facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier in the federal pharmaceutical supply chain, leveraging its woman-owned small business status to compete effectively for Defense Logistics Agency contracts. The company's extensive federal contract portfolio demonstrates consistent capability in delivering specialized pharmaceutical products, including biologics and specialty medications, directly to Department of Defense healthcare sites. This particular order for Xolair—a monoclonal antibody used primarily for asthma and urticaria treatment—exemplifies the company's role in supplying critical prescription medications to military health facilities across the nation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.7k | 9/26/25 |